Regulation of the mdm2 Oncogene by Thyroid Hormone Receptor
暂无分享,去创建一个
H. Samuels | J. Qi | Yaping Yuan | V. Desai-Yajnik | Herbert H. Samuels | Vandana Desai-Yajnik | Jian-Shen Qi | Yaping Yuan
[1] M. Surks,et al. L-triiodothyronine (T3) regulates cellular growth rate, growth hormone production, and levels of nuclear T3 receptors via distinct dose-response ranges in cultured GC cells. , 1990, Endocrinology.
[2] V K Chatterjee,et al. Negative regulation of the thyroid-stimulating hormone alpha gene by thyroid hormone: receptor interaction adjacent to the TATA box. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[3] J. Landers,et al. Physical and functional interaction between wild-type p53 and mdm2 proteins , 1994, Molecular and cellular biology.
[4] Tony Kouzarides,et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein , 1995, Nature.
[5] B. Desvergne,et al. Functional characterization and receptor binding studies of the malic enzyme thyroid hormone response element. , 1991, The Journal of biological chemistry.
[6] A. Levine,et al. The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.
[7] H. Samuels,et al. Characterization of the domain structure of chick c-erbA by deletion mutation: in vitro translation and cell transfection studies. , 1989, Molecular endocrinology.
[8] B. O’Malley,et al. COUP transcription factor is a member of the steroid receptor superfamily , 1989, Nature.
[9] B. Vogelstein,et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.
[10] M. Ladanyi,et al. MDM2 gene amplification in metastatic osteosarcoma. , 1993, Cancer research.
[11] H. Stunnenberg,et al. Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product , 1989, Nature.
[12] J. Harney,et al. Mutations of the rat growth hormone promoter which increase and decrease response to thyroid hormone define a consensus thyroid hormone response element. , 1989, Molecular endocrinology.
[13] W. Sellers,et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2 , 1995, Nature.
[14] H. Samuels,et al. pEXPRESS: a family of expression vectors containing a single transcription unit active in prokaryotes, eukaryotes and in vitro. , 1991, Gene.
[15] E. Appella,et al. H-2RIIBP expressed from a baculovirus vector binds to multiple hormone response elements. , 1992, Molecular Endocrinology.
[16] E. Shaulian,et al. Induction of Mdm2 and enhancement of cell survival by bFGF , 1997, Oncogene.
[17] K. Umesono,et al. Retinoic acid and thyroid hormone induce gene expression through a common responsive element , 1988, Nature.
[18] H. Samuels,et al. A domain containing leucine-zipper-like motifs mediate novel in vivo interactions between the thyroid hormone and retinoic acid receptors. , 1989, Molecular endocrinology.
[19] M. Oren,et al. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. , 1993, Oncogene.
[20] M. Zenke,et al. Unliganded T3R, but not its oncogenic variant, v‐erbA, suppresses RAR‐dependent transactivation by titrating out RXR. , 1993, The EMBO journal.
[21] T. Soussi,et al. Structural aspects of the p53 protein in relation to gene evolution. , 1990, Oncogene.
[22] A. Cooney,et al. Chicken ovalbumin upstream promoter transcription factor (COUP-TF) dimers bind to different GGTCA response elements, allowing COUP-TF to repress hormonal induction of the vitamin D3, thyroid hormone, and retinoic acid receptors , 1992, Molecular and cellular biology.
[23] H. Samuels,et al. Photoaffinity labeling of thyroid hormone nuclear receptors. Influence of n-butyrate and analysis of the half-lives of the 57,000 and 47,000 molecular weight receptor forms. , 1984, The Journal of biological chemistry.
[24] Steven M. Lipkin,et al. The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors , 1991, Cell.
[25] H. Samuels,et al. The NF-kappa B and Sp1 motifs of the human immunodeficiency virus type 1 long terminal repeat function as novel thyroid hormone response elements , 1993, Molecular and cellular biology.
[26] H. Samuels,et al. An arginine to histidine mutation in codon 311 of the C-erbA beta gene results in a mutant thyroid hormone receptor that does not mediate a dominant negative phenotype. , 1993, The Journal of clinical investigation.
[27] P. Meltzer,et al. Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.
[28] K. Kinzler,et al. Definition of a consensus binding site for p53 , 1992, Nature Genetics.
[29] M. Lazar. Thyroid hormone receptors: multiple forms, multiple possibilities. , 1993, Endocrine reviews.
[30] Moore,et al. Functional characterization of the rat growth hormone promoter elements required for induction by thyroid hormone with and without a co-transfected beta type thyroid hormone receptor. , 1989, The Journal of biological chemistry.
[31] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[32] S. Deb,et al. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. , 1994, Oncogene.
[33] H. Samuels,et al. cis-acting elements of the rat growth hormone gene which mediate basal and regulated expression by thyroid hormone. , 1987, The Journal of biological chemistry.
[34] B. Wasylyk,et al. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. , 1995, Oncogene.
[35] M. Oren,et al. mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.
[36] A. Levine,et al. The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.
[37] H. Samuels,et al. Thyroid hormone receptor/and v-erbA. A single amino acid difference in the C-terminal region influences dominant negative activity and receptor dimer formation. , 1991, The Journal of biological chemistry.
[38] A. Levine,et al. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. , 1992, Genes & development.
[39] H. Stunnenberg,et al. A major thyroid hormone response element in the third intron of the rat growth hormone gene. , 1990, The EMBO journal.
[40] B. Vogelstein,et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[41] B. Raaka,et al. The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediates diverse responses by affecting heterodimer but not homodimer formation , 1993, Molecular and cellular biology.
[42] U. Francke,et al. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line , 1987, Somatic cell and molecular genetics.
[43] P. Larsen,et al. Identification of a thyroid hormone receptor that is pituitary-specific. , 1989, Science.
[44] R. Evans,et al. The steroid and thyroid hormone receptor superfamily. , 1988, Science.
[45] B. Raaka,et al. A 10-amino-acid sequence in the N-terminal A/B domain of thyroid hormone receptor alpha is essential for transcriptional activation and interaction with the general transcription factor TFIIB , 1995, Molecular and cellular biology.
[46] M. Remm,et al. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. , 1992, Oncogene.
[47] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[48] J. Landers,et al. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. , 1994, Oncogene.
[49] S. Fields,et al. Presence of a potent transcription activating sequence in the p53 protein. , 1990, Science.
[50] D. George,et al. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.
[51] K. Umesono,et al. Determinants of target gene specificity for steroid/thyroid hormone receptors , 1989, Cell.
[52] H. Samuels,et al. Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model. , 1990, Molecular endocrinology.
[53] B. O’Malley,et al. Purification and characterization of chicken ovalbumin gene upstream promoter transcription factor from homologous oviduct cells , 1987, Molecular and cellular biology.
[54] M. Oren,et al. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. , 1995, Nucleic acids research.
[55] H. Samuels,et al. Interactions of thyroid hormone receptor with the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and the HIV-1 Tat transactivator , 1995, Journal of virology.
[56] H. Samuels,et al. c-erbA protooncogenes mediate thyroid hormone-dependent and independent regulation of the rat growth hormone and prolactin genes. , 1988, Molecular endocrinology.
[57] B. Raaka,et al. Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptors and related factors bind to DNA response elements as monomers, homodimers, or heterodimers. , 1992, Molecular endocrinology.
[58] K. Umesono,et al. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors , 1991, Cell.
[59] B M Raaka,et al. The ligand-binding domains of the thyroid hormone/retinoid receptor gene subfamily function in vivo to mediate heterodimerization, gene silencing, and transactivation , 1995, Molecular and cellular biology.
[60] A. Cooney,et al. Multiple mechanisms of chicken ovalbumin upstream promoter transcription factor-dependent repression of transactivation by the vitamin D, thyroid hormone, and retinoic acid receptors. , 1993, The Journal of biological chemistry.
[61] C. Prives,et al. p53: puzzle and paradigm. , 1996, Genes & development.
[62] A. Levine,et al. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. , 1993, Oncogene.
[63] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[64] T. Léveillard,et al. The MDM2 C-terminal Region Binds to TAFII250 and Is Required for MDM2 Regulation of the Cyclin A Promoter* , 1997, The Journal of Biological Chemistry.
[65] H. Samuels,et al. Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression , 1997, Molecular and cellular biology.
[66] Arnold J. Levine,et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.
[67] J. E. Stenger,et al. p53 domains: identification and characterization of two autonomous DNA-binding regions. , 1993, Genes & development.
[68] C. Finlay,et al. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth , 1993, Molecular and cellular biology.